A Phase III, Open-Label, Randomised, Multicentre, Global Study of Adjuvant Datopotamab Deruxtecan in Combination with Rilvegostomig in Participants with High-risk Muscle Invasive Urothelial Carcinoma (TROPION-Urothelial04)

Clinical Trial Information

Trial Phone: 321-841-7246

Principal Investigator: Jad Chahoud, MD

Phase: III

Age Group: ADULTOLDER_ADULT

ClinicalTrials.gov ID: NCT07720284

Objective

This study is looking at whether Dato-DXd plus rilvegostomig works better than standard treatment by measuring how long participants with muscle-invasive urothelial cancer and high-risk disease after surgery remain free of cancer recurrence or progression.

Share:

Related Clinical Trials

An Interventional Phase III, Open-Label, Randomized Study to Evaluate Efficacy and Safety of PF-08634404 in Combination with Chemotherapy versus Pembrolizumab in Combination with Chemotherapy in Adult Participants with Advanced or Recurrent Mismatch Repair Proficient Endometrial Cancer
Study of a New Device for Severe Asthma (PULSAR)
A Randomized, Open-Label Phase III Study of Azenosertib versus Investigator's Choice of Chemotherapy in Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
Multicenter research for the application and verification of the performance of the Necker Cranial Injury Scale (NCIS) as a predictor of in-hospital mortality in children and adolescents (<17 y-o) with severe traumatic brain injury (sTBI)